caa a22 4500 445326298 CHVBK 20180317142721.0 cr unu---uuuuu 170323e20110301xx s 000 0 eng 10.1007/s10989-010-9234-8 doi (NATIONALLICENCE)springer-10.1007/s10989-010-9234-8 Attenuation of Neuronal Death by Peptide Inhibitors of AP-1 Activation in Acute and Delayed In Vitro Ischaemia (Oxygen/Glucose Deprivation) Models [Elektronische Daten] [Amanda Craig, Bruno Meloni, Paul Watt, Neville Knuckey] Using acute and delayed in vitro ischaemia models we evaluated the neuroprotective efficacy of five peptides (PYC19D-TAT, PYC35D-TAT, PYC36D-TAT, PYC38D-TAT, PYC41D-TAT) previously demonstrated to down-regulate AP-1 activation (e.g. c-Jun/c-Fos activation), and inhibit neuronal death in vitro following glutamate and kainic acid excitotoxicity. The JNK inhibitor peptide (JNKI-1D-TAT) and the TAT cell-penetrating-carrier peptide (D-TAT) were used as controls. In the acute model, all five AP-1 inhibitory peptides, JNKI-1D-TAT, and D-TAT provided neuroprotection by increasing neuronal viability from ≈5 to 23-53%. In the delayed model, three of the five AP-1 inhibitory peptides (PYC35D-TAT, PYC36D-TAT, PYC38D-TAT) and JNKI-1D-TAT provided neuroprotection by increasing neuronal viability from ≈10 to 35-80%. This study not only highlights a group of peptides with therapeutic potential, but also the need to assess putative therapeutics in multiple in vitro models to achieve a comprehensive representation of their neuroprotective capacity. Springer Science+Business Media, LLC, 2010 Neuroprotection nationallicence In vitro ischaemia nationallicence AP-1 nationallicence JNKI nationallicence TAT nationallicence Craig Amanda Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Australian Neuromuscular Research Institute, A Block, 4th floor, Nedlands, WA, Australia aut Meloni Bruno Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Australian Neuromuscular Research Institute, A Block, 4th floor, Nedlands, WA, Australia aut Watt Paul Phylogica Ltd, Perth, WA, Australia aut Knuckey Neville Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Australian Neuromuscular Research Institute, A Block, 4th floor, Nedlands, WA, Australia aut International Journal of Peptide Research and Therapeutics Springer Netherlands 17/1(2011-03-01), 1-6 1573-3149 17:1<1 2011 17 10989 https://doi.org/10.1007/s10989-010-9234-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10989-010-9234-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Craig Amanda Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Australian Neuromuscular Research Institute, A Block, 4th floor, Nedlands, WA, Australia aut NATIONALLICENCE 700 1- Meloni Bruno Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Australian Neuromuscular Research Institute, A Block, 4th floor, Nedlands, WA, Australia aut NATIONALLICENCE 700 1- Watt Paul Phylogica Ltd, Perth, WA, Australia aut NATIONALLICENCE 700 1- Knuckey Neville Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Australian Neuromuscular Research Institute, A Block, 4th floor, Nedlands, WA, Australia aut NATIONALLICENCE 773 0- International Journal of Peptide Research and Therapeutics Springer Netherlands 17/1(2011-03-01), 1-6 1573-3149 17:1<1 2011 17 10989 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer